-transparent.png){kind=logo}
Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. 2006
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
Methyl protodioscin (NSC-698790) is one of the main bioactive components in the traditional Chinese medicine Dioscorea collettii var. hypoglauca (Dioscoreaceae). In this study, we investigated the anti-proliferative effect of methyl protodioscin on the HepG2 cells and the mechanism of the induced cytotoxicity. Treatment of methyl protodioscin resulted in G2/M arrest and apoptosis in HepG2 cells. These effects were attributed to down-regulation of Cyclin B1 and the signaling pathways leading to up-regulation of Bax and down-regulation of BCL2, suggesting that methyl protodioscin may be a novel anti-mitotic agent.
Related Publications
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
July 2014,
Pharmacognosy magazine,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
May 2014,
Pharmaceutical biology,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
June 2005,
Cancer letters,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
January 2011,
Anti-cancer drugs,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
January 2010,
Cancer letters,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
September 2010,
Oncology reports,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
June 2014,
International journal of molecular medicine,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
February 2015,
Oncology reports,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
August 2015,
Anti-cancer drugs,
Guanghui Wang, and
Haifeng Chen, and
Minghui Huang, and
Naili Wang, and
Jinchao Zhang, and
Yaou Zhang, and
Ganrong Bai, and
Wang-Fun Fong, and
Mengsu Yang, and
Xinsheng Yao
November 2017,
Molecular medicine reports,
